Transforming growth factor-beta 1 (TGF-beta 1) in patients with amyotrophic lateral sclerosis

Cytokine

Volumn 20, Issue 5, 2002, Pages 239-243

  Iłz̈ecka, Joanna ^a   Stelmasiak, Zbigniew ^a   Dobosz, Beata ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Amyotrophic lateral sclerosis; Neurodegeneration; Transforming growth factor beta 1 (TGF beta 1)

Indexed keywords

BIOCHEMICAL MARKER; TRANSFORMING GROWTH FACTOR BETA1; TGFB1 PROTEIN, HUMAN; TRANSFORMING GROWTH FACTOR BETA;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE DURATION; DISEASE MARKER; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEALTH STATUS; HUMAN; MALE; NERVE DEGENERATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN FUNCTION; BLOOD; HOSPITALIZATION; MIDDLE AGED; PATHOPHYSIOLOGY;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

EID: 0041805449     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1006/cyto.2002.2005     Document Type: Article

References (27)

1. Kruman I.I., Pedersen W.A., Springer J.E., Mattson M.P. ALS-linked Cu/Zn-SOD mutation increases vulnerability of motor neurons to excitotoxicity by a mechanism involving increased oxidative stress and perturbed calcium homeostasis. Exp Neurol. 160:1999;28-39.
2. Choi M.E. Mechanism of transforming growth factor-beta 1 signaling. Kidney Int. 77:2000;53-58.
3. Lawrence D.A. Transforming growth factor-beta: a general review. Eur Cytokine Netw. 7:1996;363-374.
4. Noble N.A., Harper J.R., Border W.A. In vivo interactions of TGF-beta and extracellular matrix. Prog Growth Factor Res. 4:1992;369-382.
5. Barcellos-Hoff M.H., Dix T.A. Redox-mediated activation of latent transforming growth factor-beta 1. Mol Endocrinol. 10:1996;1077-1083.
6. Prehn J.H., Bindokas V.P., Jordan J., Galindo M.F., Ghadge G.D., Roos R.P., Boise L.H., Thompson C.B., Krajewski S., Reed J.C., Miller R.J. Protective effect of transforming growth factor-beta 1 on beta-amyloid neurotoxicity in rat hippocampal neurons. Mol Pharmacol. 49:1996;319-328.
7. Lippa C.F., Smith T.W., Flanders K.C. Transforming growth factor-beta: neuronal and glial expression in CNS degenerative diseases. Neurodegeneration. 4:1995;425-432.
8. Murakami N., McLennan I.S., Nonaka I., Koishi K., Baker C., Hammond-Tooke G. Transforming growth factor-beta 2 is elevated in skeletal muscle disorders. Muscle Nerve. 22:1999;889-898.
9. Finch C.E., Laping N.J., Morgan T.E., Nichols N.R., Pasinetti G.M. TGF-beta 1 is an organizer of responses to neurodegeneration. J Cell Biochem. 53:1993;314-322.
10. Flanders K.C., Ren R.F., Lippa C.F. Transforming growth factor-betas in neurodegenerative disease. Prog Neurobiol. 54:1998;71-85.
11. Mattson M.P., Barger S.W., Furukawa K., Bruce A.J., Wyss-Coray T., Mark R.J., Mucke L. Cellular signaling roles of TGF beta, TNF alpha and beta APP in brain injury responses and Alzheimer's disease. Brain Res Rev. 23:1997;47-61.
12. Brooks B.R. El Escorial Word Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. J Neurol Sci. 124:1994;96-107.
13. Riviere M., Meininger V., Zeisser P., Munsat T. An analysis of extended survival in patients with amyotrophic lateral sclerosis treated with riluzole. Arch Neurol. 55:1998;526-528.
14. Grainger D.J., Mosedale D.E., Metcalfe J.C. TGF-beta in blood: a complex problem. Cytokine Growth Factor Rev. 11:2000;133-145.
15. Limper A.H. Detection of TGF-beta in body fluids and tissues. Methods Mol Biol. 142:2000;39-54.
16. Pratt B.M., McPherson J.M. TGF-beta in the central nervous system: potential roles in ischemic injury and neurodegenerative diseases. Cytokine Growth Factor Rev. 8:1997;267-292.
17. Prehn J.H., Peruche B., Unsicker K., Krieglstein J. Isoform-specific effects of transforming growth factors-beta on degeneration of primary neuronal cultures induced by cytotoxic hypoxia or glutamate. J Neurochem. 60:1993;1665-1672.
18. Henrich-Noack P., Prehn J.H., Krieglstein J. Neuroprotective effects of TGF-beta 1. J Neural Transm. 43:1994;33-45.
19. Mogi M., Harada M., Kondo T., Narabayashi H., Riederer P., Nagatsu T. Transforming growth factor-beta 1 levels are elevated in the striatum and in ventricular cerebrospinal fluid in Parkinson's disease. Neurosci Lett. 193:1995;129-132.
20. Chao C.C., Ala T.A., Hu S., Crossley K.B., Sherman R.E., Peterson P.K., Frey W.H. 2nd. Serum cytokine levels in patients with Alzheimer's disease. Clin Diagn Lab Immunol. 1:1994;433-436.
21. Schiffer D., Cordera S., Cavalla P., Migheli A. Reactive astrogliosis of the spinal cord in amyotrophic lateral sclerosis. J Neurol Sci. 139:1996;27-33.
22. Fujita K., Kato T., Yamauchi M., Ando M., Honda M., Nagata Y. Increases in fragmented glial fibrillary acidic protein levels in the spinal cords of patients with amyotrophic lateral sclerosis. Neurochem Res. 23:1998;169-174.
23. Nagata Y., Fujita K., Yamauchi M., Kato T., Ando M., Honda M. Neurochemical changes in the spinal cord in degenerative motor neuron diseases. Mol Chem Neuropathol. 33:1998;237-247.
24. Laping N.J., Morgan T.E., Nichols N.R., Rozovsky I., Young-Chan C.S., Zarow C., Finch C.E. Transforming growth factor-beta 1 induces neuronal and astrocyte genes: tubulin alpha 1, glial fibrillary acidic protein and clusterin. Neuroscience. 58:1994;563-572.
25. Reilly J.F., Maher P.A., Kumari V.G. Regulation of astrocyte GFAP expression by TGF-beta 1 and FGF-2. Glia. 22:1998;202-210.
26. McGeer P.L., McGeer E.G. Glial cell reactions in neurodegenerative diseases: pathophysiology and therapeutic interventions. Alzheimer Dis Assoc Disord. 12:1998;1-6.
27. Shahani N., Nalini A., Gourie-Devi M., Raju T.R. Reactive astrogliosis in neonatal rat spinal cord after exposure to cerebrospinal fluid from patients with amyotrophic lateral sclerosis. Exp Neurol. 149:1998;295-298.